Support and Resistance Basics
What is MACD and how to read it?
How RSI can help?
Stock Summary
Top Correlated Resources
ATGE
Top 10 Correlated ETFs
ATGE
Top 10 Correlated Stocks
ATGE
In the News
Adtalem (ATGE) Q3 Earnings & Revenue Beat, Margins Rise Y/Y
Adtalem Global Education's (ATGE) fourth-quarter fiscal 2022 results reflect benefits from Walden acquisition and cost synergies.
Adtalem Global Education, Inc. (ATGE) CEO Stephen Beard on Q4 2022 Results - Earnings Call Transcript
Adtalem Global Education, Inc. (NYSE:ATGE ) Q4 2022 Earnings Conference Call August 11, 2022 5:00 PM ET Company Participants Chandrika Nigam - Director, IR Stephen Beard - President, CEO & Director Robert Phelan - SVP & CFO Conference Call Participants Jeffrey Meuler - Robert W. Baird & Co. Jeffrey Silber - BMO Capital Markets Operator Greetings.
3 School Stocks Set to Gain Despite Industry Headwinds
Virtual delivery of education and prudent cost-saving initiatives are likely to open up opportunities for LRN, ATGE and PRDO. Fed's hawkish moves and higher costs are risks for the Zacks Schools industry.
Adtalem Global (ATGE) to Post Q4 Earnings: What to Expect?
More operational efficiency and realization of cost synergies associated with the Walden integration should aid Adtalem Global Education's (ATGE) fiscal Q4 earnings.
Adtalem Global Education Announces Fiscal Fourth Quarter and Full Year 2022 Conference Call
CHICAGO--(BUSINESS WIRE)--Adtalem Global Education Inc. (NYSE: ATGE), a leading healthcare educator, announced today it will hold a conference call to discuss its fiscal 2022 fourth quarter and full year results on Thursday, Aug. 11, 2022, at 4 p.m. CT (5 p.m. EDT). The conference call will be led by Steve Beard, president and chief executive officer, and Bob Phelan, senior vice president and chief financial officer. For those participating by telephone, dial 877-407-6184 (United States) or +1
3 Education Stocks to Enroll in This Summer
With so many companies competing to reach the head of the class, choosing winning education stocks is a brain teaser. When it comes to good long-term growth prospects, these three names make the grade.
Adtalem (ATGE) Up 17.4% in Last 6 Months: Factors to Note
Adtalem (ATGE) benefits from solid demand for healthcare programs and offerings.
Top 5 Consumer Discretionary Picks Defying Sector's Bloodbath
We have narrowed our search to five consumer discretionary stocks that have popped with double-digit returns year to date. These are: HRB, MAT, NXST, LRN and ATGE.
Can Adtalem (ATGE) Run Higher on Rising Earnings Estimates?
Adtalem (ATGE) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
3 Online Education Stocks Investors Should Study
A study conducted by Global Market Insights (GMI) concluded that the global e-learning market will grow 20% annually over the next seven years and cross the $1 trillion mark by 2028. Gaining knowledge about which stocks to buy should involve studying these three companies.
Financial details
Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-06-30
| Metric | History | 2017-06-30 | 2018-06-30 | 2019-06-30 | 2020-06-30 | 2021-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 28.56 | 20.05 | 21.23 | 19.61 | 21.67 | |
| Net income per share | 1.93 | 0.55 | 1.63 | -1.59 | 1.5 | |
| Operating cash flow per share | 3.6 | 3.9 | 3.51 | 2.01 | 3.74 | |
| Free cash flow per share | 2.82 | 2.81 | 2.4 | 1.18 | 2.8 | |
| Cash per share | 3.88 | 7.08 | 5.28 | 9.49 | 9.64 | |
| Book value per share | 26.34 | 24.74 | 23.83 | 24.42 | 25.35 | |
| Tangible book value per share | 6.38 | 5.58 | 1.7 | 6.27 | 6.59 | |
| Share holders equity per share | 26.34 | 24.74 | 23.83 | 24.42 | 25.35 | |
| Interest debt per share | 2.12 | 5.01 | 7.27 | 9.99 | 26.02 | |
| Market cap | 2.09B | 3.36B | 2.86B | 1.87B | 1.87B | |
| Enterprise value | 1.97B | 3.22B | 2.96B | 1.88B | 2.66B | |
| P/E ratio | 17.07 | 99.55 | 30.04 | -21.86 | 24.25 | |
| Price to sales ratio | 1.15 | 2.73 | 2.31 | 1.77 | 1.68 | |
| POCF ratio | 9.16 | 14.05 | 13.96 | 17.32 | 9.7 | |
| PFCF ratio | 11.66 | 19.47 | 20.41 | 29.36 | 12.99 | |
| P/B Ratio | 1.25 | 2.21 | 2.05 | 1.42 | 1.43 | |
| PTB ratio | 1.25 | 2.21 | 2.05 | 1.42 | 1.43 | |
| EV to sales | 1.09 | 2.62 | 2.39 | 1.79 | 2.4 | |
| Enterprise value over EBITDA | 8.72 | 17.4 | 14.46 | 65.37 | 10.98 | |
| EV to operating cash flow | 8.64 | 13.48 | 14.45 | 17.48 | 13.86 | |
| EV to free cash flow | 11.01 | 18.67 | 21.13 | 29.61 | 18.56 | |
| Earnings yield | 0.06 | 0.01 | 0.03 | -0.05 | 0.04 | |
| Free cash flow yield | 0.09 | 0.05 | 0.05 | 0.03 | 0.08 | |
| Debt to equity | 0.07 | 0.19 | 0.29 | 0.35 | 0.95 | |
| Debt to assets | 0.28 | 0.35 | 0.38 | 0.41 | 0.57 | |
| Net debt to EBITDA | -0.52 | -0.74 | 0.5 | 0.57 | 3.3 | |
| Current ratio | 1.25 | 1.88 | 1.62 | 2 | 3.71 | |
| Interest coverage | 15.16 | 14.19 | 7.87 | 7.29 | 3.9 | |
| Income quality | 1.86 | 7.08 | 2.15 | -1.26 | 2.5 | |
| Dividend Yield | 0.01 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0.09 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.34 | 0.3 | 0.32 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.55 | 0.5 | 0.58 | 0.44 | 0.32 | |
| Capex to operating cash flow | -0.21 | -0.28 | -0.32 | -0.41 | -0.25 | |
| Capex to revenue | -0.03 | -0.05 | -0.05 | -0.04 | -0.04 | |
| Capex to depreciation | -0.58 | -1.26 | -1.25 | -0.44 | -0.49 | |
| Stock based compensation to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Graham number | 33.82 | 17.5 | 29.57 | 29.56 | 29.24 | |
| ROIC | 0.07 | 0.1 | 0.1 | 0.08 | 0.06 | |
| Return on tangible assets | 0.12 | 0.03 | 0.1 | -0.07 | 0.04 | |
| Graham Net | -4.25 | -4.57 | -7.27 | -6.4 | -23.52 | |
| Working capital | 93.88M | 322.22M | 193.07M | 346.78M | 1.11B | |
| Tangible asset value | 403.95M | 342.47M | 98.98M | 336.69M | 338.45M | |
| Net current asset value | -173.79M | -137.68M | -346.47M | -225.5M | -237.81M | |
| Invested capital | 0.07 | 0.19 | 0.29 | 0.39 | 0.99 | |
| Average receivables | 130.2M | 116.88M | 122.44M | 87.04M | 77.52M | |
| Average payables | 55.38M | 46.98M | 52.06M | 46.48M | 51.28M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 34.96 | 43.5 | 46.47 | 30.2 | 22.31 | |
| Days payables outstanding | 24.39 | 26.84 | 33.73 | 34.62 | 41.83 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 10.44 | 8.39 | 7.85 | 12.09 | 16.36 | |
| Payables turnover | 14.97 | 13.6 | 10.82 | 10.54 | 8.73 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.07 | 0.02 | 0.07 | -0.07 | 0.06 | |
| Capex per share | -0.77 | -1.08 | -1.11 | -0.82 | -0.95 |
Quarterly Fundamentals Overview
Last date of statement is 2022-03-31 for Q3
| Metric | History | 2021-03-31 | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 5.54 | 5.62 | 7.01 | 7.46 | 7.47 | |
| Net income per share | 0.49 | 0.18 | -1.17 | 0.36 | 7.15 | |
| Operating cash flow per share | 1.59 | 0.96 | 0.82 | -0.38 | 1.03 | |
| Free cash flow per share | 1.38 | 0.69 | 0.68 | -0.68 | 0.88 | |
| Cash per share | 10.04 | 9.92 | 7.25 | 5.53 | 16.12 | |
| Book value per share | 25.79 | 26.08 | 25.48 | 25.87 | 30.48 | |
| Tangible book value per share | 6.71 | 6.78 | -23.24 | -11.94 | -7.5 | |
| Share holders equity per share | 25.79 | 26.08 | 25.48 | 25.87 | 30.48 | |
| Interest debt per share | 25.63 | 26.45 | 37.27 | 41.18 | 30.45 | |
| Market cap | 2B | 1.78B | 1.88B | 1.47B | 1.45B | |
| Enterprise value | 2.8B | 2.58B | 3.35B | 3.27B | 2.13B | |
| P/E ratio | 20.31 | 49.32 | -8.09 | 20.6 | 1.04 | |
| Price to sales ratio | 7.14 | 6.34 | 5.39 | 3.96 | 3.98 | |
| POCF ratio | 24.8 | 37.01 | 45.95 | -77.57 | 28.85 | |
| PFCF ratio | 28.57 | 51.96 | 55.99 | -43.61 | 33.87 | |
| P/B Ratio | 1.53 | 1.37 | 1.48 | 1.14 | 0.97 | |
| PTB ratio | 1.53 | 1.37 | 1.48 | 1.14 | 0.97 | |
| EV to sales | 9.96 | 9.19 | 9.61 | 8.81 | 5.83 | |
| Enterprise value over EBITDA | 42.72 | 41.74 | -1.09K | 42.03 | 5.14 | |
| EV to operating cash flow | 34.61 | 53.65 | 81.88 | -172.48 | 42.28 | |
| EV to free cash flow | 39.87 | 75.32 | 99.76 | -96.97 | 49.65 | |
| Earnings yield | 0.01 | 0.01 | -0.03 | 0.01 | 0.24 | |
| Free cash flow yield | 0.03 | 0.02 | 0.02 | -0.02 | 0.03 | |
| Debt to equity | 0.94 | 0.95 | 1.39 | 1.48 | 0.95 | |
| Debt to assets | 0.57 | 0.57 | 0.66 | 0.65 | 0.58 | |
| Net debt to EBITDA | 12.11 | 12.95 | -477.16 | 23.13 | 1.63 | |
| Current ratio | 3.92 | 3.71 | 1.12 | 1.23 | 1.94 | |
| Interest coverage | 5.17 | 1.59 | -0.21 | -0.95 | 1.38 | |
| Income quality | 3.28 | 5.33 | -0.7 | -1.06 | 0.14 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.32 | 0.32 | 0.64 | 0.51 | 0.53 | |
| Capex to operating cash flow | -0.13 | -0.29 | -0.18 | 0.78 | -0.15 | |
| Capex to revenue | -0.04 | -0.05 | -0.02 | -0.04 | -0.02 | |
| Capex to depreciation | -0.43 | -0.58 | -0.17 | -0.32 | -0.15 | |
| Stock based compensation to revenue | 0.01 | 0.01 | 0.03 | 0.04 | 0.01 | |
| Graham number | 16.8 | 10.3 | 25.87 | 14.45 | 70.03 | |
| ROIC | 0.02 | 0.02 | 0 | 0.01 | 0.01 | |
| Return on tangible assets | 0.01 | 0 | -0.04 | 0.01 | 0.21 | |
| Graham Net | -22.86 | -24.2 | -40.68 | -40.68 | -23.84 | |
| Working capital | 1.12B | 1.11B | 73.56M | 113.03M | 489.79M | |
| Tangible asset value | 339.69M | 338.45M | -1.15B | -594.08M | -366.84M | |
| Net current asset value | -227.5M | -237.81M | -1.79B | -1.76B | -1.02B | |
| Invested capital | 0.99 | 0.99 | 1.45 | 1.61 | 0.98 | |
| Average receivables | 85.15M | 80.37M | 127.98M | 92.74M | 94.4M | |
| Average payables | 55.69M | 60.75M | 89.5M | 65.42M | 66.34M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 24.87 | 21.83 | 42.17 | 22.49 | 23.65 | |
| Days payables outstanding | 33.61 | 40.17 | 62.67 | 17.63 | 36.46 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 3.62 | 4.12 | 2.13 | 4 | 3.81 | |
| Payables turnover | 2.68 | 2.24 | 1.44 | 5.11 | 2.47 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.02 | 0.01 | -0.05 | 0.01 | 0.23 | |
| Capex per share | -0.21 | -0.28 | -0.15 | -0.3 | -0.15 |
Company Profile
- Volume Average 480.74K
- Market Capitalization 1.73B
- Employee 10K
- CEO Ms. Lisa Wardell
- Headquarters Chicago,ILLINOIS,US
- IPO Date 1995-11-14
-
Website
https://www.adtalem.com 
Adtalem Global Education Inc. provides workforce solutions worldwide. It operates through two segments, Medical and Healthcare; and Financial Services. The Medical and Healthcare segment offers degree and non-degree programs in the medical and healthcare postsecondary education industry. This segment operates Chamberlain University, American University of the Caribbean School of Medicine, Ross University School of Medicine, and Ross University School of Veterinary Medicine. The Financial Services segment provides test preparation, certifications, conferences, seminars, memberships, and subscriptions to business professionals in the areas of accounting, anti-money laundering, banking, and mortgage lending. It operates Association of Certified Anti-Money Laundering Specialists, Becker Professional Education, OnCourse Learning, and EduPristine. The company was formerly known as DeVry Education Group Inc. and changed its name to Adtalem Global Education Inc. in May 2017. Adtalem Global Education Inc. was incorporated in 1987 and is based in Chicago, Illinois.
